{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:00:18Z","timestamp":1785895218156,"version":"3.56.0"},"reference-count":43,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Liver Journal"],"published-print":{"date-parts":[[2023,7,26]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Direct-acting antiviral (DAA) therapies have simplified HCV treatment, and publicly funded Canadian drug plans have eliminated disease-stage restrictions for reimbursement of DAA therapies. However other policies which complicate, delay, or prevent treatment initiation still persist. We aim to describe these plans\u2019 existing reimbursement criteria and appraise whether they hinder treatment access. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> We reviewed DAA reimbursement policies of 16 publicly funded drug plans published online and provided by contacts with in-depth knowledge of prescribing criteria. Data were collected from May to July 2022. Primary outcomes were: (1) if plans have arranged to accept point-of-care HCV RNA testing for diagnosis; testing requirements for (2) HCV genotype, (3) fibrosis stage, and (4) chronic infection; (5) time taken and method used to approve reimbursement requests; (6) providers eligible to prescribe DAAs; and (7) restrictions on re-treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Fifteen (94%) plans have at least one policy in place which limits simplified HCV treatment. Many plans continue to require results of genotype or fibrosis staging, limit eligible prescribers, and take longer than 1 day to approve coverage requests. One plan discourages treatment for re-infection. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Reimbursement criteria set by publicly funded Canadian drug plans continue to limit timely, equitable access to HCV treatment. Eliminating clinically irrelevant pre-authorization testing, expanding eligible prescribers, expediting claims processing, and broadening coverage of treatment for reinfection will improve access to DAAs. The federal government could further enhance efforts by introducing a federal HCV elimination strategy or federal high-cost drug PharmaCare program. <\/jats:p><\/jats:sec>","DOI":"10.3138\/canlivj-2022-0040","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:09:10Z","timestamp":1690376950000},"page":"190-200","source":"Crossref","is-referenced-by-count":15,"title":["Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study"],"prefix":"10.3138","volume":"6","author":[{"given":"Gaelen","family":"Snell","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison D","family":"Marshall","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"The Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"van Gennip","sequence":"additional","affiliation":[{"name":"Action Hepatitis Canada, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bonn","sequence":"additional","affiliation":[{"name":"Canadian Association of People Who Use Drugs, Dartmouth, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Butler-McPhee","sequence":"additional","affiliation":[{"name":"HIV Legal Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis L","family":"Cooper","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Kronfli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montr\u00e9al, Quebec, Canada"},{"name":"Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Williams","sequence":"additional","affiliation":[{"name":"Calgary Liver Unit, Alberta Health Services, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al Research Center, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed Z","family":"Janjua","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montr\u00e9al, Quebec, Canada"},{"name":"Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nance","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia R","family":"Bartlett","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"key":"r1","unstructured":"Reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2030: a pan-Canadian STBBI framework for action; 2018. https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/sexual-health-sexually-transmitted-infections\/reports-publications\/sexually-transmitted-blood-borne-infections-action-framework.html. (Accessed February 17, 2022)."},{"key":"r2","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.eclinm.2019.12.007","volume":"18","author":"Zoratti MJ","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"20","key":"r3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"Afdhal N","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"r4","first-page":"195","volume":"25","author":"Yin S","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"r5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40545-018-0154-x","volume":"11","author":"Brandt J","year":"2018","journal-title":"J Pharm Policy Pract"},{"key":"r6","volume-title":"Catastrophic Drug Coverage in Canada","author":"Phillips K","year":"2016"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2020-0041"},{"key":"r8","volume-title":"Understanding the Gap 2.0 A Pan-Canadian Analysis of Prescription Drug Insurance Coverage","author":"Gagnon-Arpin IW","year":"2022"},{"issue":"22","key":"r9","doi-asserted-by":"crossref","first-page":"E677","DOI":"10.1503\/cmaj.170453","volume":"190","author":"Shah H","year":"2018","journal-title":"Can Med Assoc J"},{"issue":"4","key":"r10","doi-asserted-by":"crossref","first-page":"E605","DOI":"10.9778\/cmajo.20160008","volume":"4","author":"Marshall AD","year":"2016","journal-title":"CMAJ Open"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.2019-0007"},{"issue":"12","key":"r12","doi-asserted-by":"crossref","first-page":"e055142","DOI":"10.1136\/bmjopen-2021-055142","volume":"11","author":"Markby J","year":"2021","journal-title":"BMJ Open"},{"issue":"4","key":"r13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/pubmed\/fdy190","volume":"41","author":"Simpson H","year":"2019","journal-title":"J Public Health (Oxf)"},{"key":"r14","unstructured":"The Canadian Network on Hepatitis C Blueprint, Writing Committee and Working Groups. Blueprint to Inform Hepatitis C Elimination Efforts in Canada [Internet]; 2019 May. Available from: http:\/\/www.canhepc.ca\/sites\/default\/files\/media\/documents\/blueprint_hcv_2019_05.pdf. (Accessed February 17, 2022)."},{"issue":"3","key":"r15","doi-asserted-by":"crossref","first-page":"e25013","DOI":"10.1002\/jia2.25013","volume":"20","author":"Saeed S","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"r16","unstructured":"Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report. Toronto, ON; 2021. https:\/\/www.actionhepatitiscanada.ca\/uploads\/8\/3\/3\/9\/83398604\/ahc_progress_report_2021.pdf. (Accessed February 17, 2022)."},{"issue":"8","key":"r17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jvh.12684","volume":"24","author":"Janjua NZ","year":"2017","journal-title":"J Viral Hepat"},{"issue":"4","key":"r18","doi-asserted-by":"crossref","first-page":"E674","DOI":"10.9778\/cmajo.20190068","volume":"7","author":"Kronfli N","year":"2019","journal-title":"CMAJ Open"},{"issue":"5","key":"r19","doi-asserted-by":"crossref","first-page":"e204192","DOI":"10.1001\/jamanetworkopen.2020.4192","volume":"3","author":"Binka M","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"r20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","volume":"167","author":"Kattakuzhy S","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"r21","doi-asserted-by":"crossref","first-page":"21382","DOI":"10.1038\/s41598-021-00362-y","volume":"11","author":"Adee M","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"r22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jval.2021.08.006","volume":"25","author":"Wong WWL","year":"2022","journal-title":"Value Health"},{"key":"r23","unstructured":"The Newfoundland and Labrador Prescription Drug Program (NLPDP). Special Authorization Request Form: Request for Coverage Hepatitis C Treatments [Internet]. Available from: https:\/\/www.gov.nl.ca\/hcs\/files\/forms-pdf-hepatitis-c-treatment-request.pdf. (Accessed February 17, 2022)."},{"issue":"3","key":"r24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jvh.12859","volume":"25","author":"Falade-Nwulia O","year":"2018","journal-title":"J Viral Hepat"},{"key":"r25","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"Amoako A","year":"2021","journal-title":"Int J Drug Policy"},{"key":"r26","doi-asserted-by":"crossref","first-page":"103422","DOI":"10.1016\/j.drugpo.2021.103422","volume":"96","author":"Carson JM","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"1","key":"r27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41124-018-0036-5","volume":"3","author":"Richmond JA","year":"2018","journal-title":"Hepatol Med Policy"},{"key":"r28","doi-asserted-by":"crossref","first-page":"103238","DOI":"10.1016\/j.drugpo.2021.103238","volume":"96","author":"Goodyear T","year":"2021","journal-title":"Int J Drug Policy"},{"key":"r29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.drugpo.2019.08.003","volume":"74","author":"Pearce ME","year":"2019","journal-title":"Int J Drug Policy"},{"key":"r30","doi-asserted-by":"crossref","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","volume":"206","author":"Marshall AD","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.2018-0012"},{"issue":"3","key":"r32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","volume":"41","author":"Gamkrelidze I","year":"2021","journal-title":"Liver Int"},{"issue":"10207","key":"r33","first-page":"1388","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"r34","unstructured":"Angus Reid Institute. Access for all: Near universal support for a pharmacare plan covering Canadians\u2019 prescription drug costs [Internet]; 2020. Available from: https:\/\/angusreid.org\/pharmacare-2020\/. (Accessed February 17, 2022)."},{"key":"r35","unstructured":"Heart & Stroke Foundation, Canadian Federation of Nurses Union. New Poll Reveals Overwhelming Support for Pharmacare [Internet]. Ottawa, ON; 2019. Available from: https:\/\/www.heartandstroke.ca\/what-we-do\/media-centre\/news-releases\/new-poll-reveals-overwhelming-support-for-pharmacare. (Accessed February 17, 2022)."},{"key":"r36","unstructured":"Fuss J, Palacios M. Polling Canadians\u2019 Support for New Federal Government Programs [Internet]. Fraser Institute; 2022. Available from: https:\/\/www.fraserinstitute.org\/sites\/default\/files\/polling-canadians-support-for-new-federal-government-programs.pdf. (Accessed February 17, 2022)."},{"key":"r37","volume-title":"A Prescription for Canada: Achieving Pharmacare for All [Internet]","author":"Advisory Council on the Implementation of National Pharmacare","year":"2019"},{"key":"r38","unstructured":"Canada G of CIS. Annual Report to Parliament 2020 [Internet]; 2020 Oct. Available from: https:\/\/www.sac-isc.gc.ca\/eng\/1602010609492\/1602010631711. (Accessed Jan 22, 2023)."},{"key":"r39","unstructured":"Affairs I. Provinces and Territories - Intergovernmental Affairs [Internet]; 2017. Available from: https:\/\/www.canada.ca\/en\/intergovernmental-affairs\/services\/provinces-territories.html. (Accessed Jan 22, 2023)."},{"issue":"4","key":"r40","first-page":"339","volume":"20","author":"Pisu M","year":"2010","journal-title":"Ethn Dis"},{"issue":"3","key":"r41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1377\/hlthaff.28.3.827","volume":"28","author":"Choudhry NK","year":"2009","journal-title":"Health Aff Proj Hope"},{"issue":"1","key":"r42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1353\/hpu.2011.0003","volume":"22","author":"Felder TM","year":"2011","journal-title":"J Health Care Poor Underserved"},{"issue":"6","key":"r43","first-page":"506","volume":"13","author":"Clay P","year":"2007","journal-title":"J Manag Care Pharm"}],"container-title":["Canadian Liver Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/canlivj-2022-0040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T17:28:52Z","timestamp":1741886932000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/canlivj-2022-0040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7,26]]}},"alternative-id":["10.3138\/canlivj-2022-0040"],"URL":"https:\/\/doi.org\/10.3138\/canlivj-2022-0040","relation":{},"ISSN":["2561-4444"],"issn-type":[{"value":"2561-4444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}